AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022.
The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters of the Rights Issue will be allocated approximately 20.8 percent of the Rights Issue thus resulting in that AlzeCure obtains SEK 48.5 million before issue costs. Those who have been allocated shares without the support of subscription rights will be notified by contract note alternatively through their nominee.
Continued progress in the 3 research platforms
“Despite an uncertain and turbulent surrounding world, both our current and new shareholders have joined this financing round. The capital injection provides AlzeCure with the necessary funds to carry out the highly interesting clinical phase II study for ACD440 as well as to continue to advance the ongoing Alzheimer projects, all of which have potential of substantial value contribution to our shareholders. We look forward to wholeheartedly devote our aggregate resources to continued progress in our three research platforms,” says Martin Jönsson, CEO AlzeCure.
Photo of Martin Jönsson: AlzeCure
